Today’s episode features a remarkable leader in the field of gene therapy, Dr. Bobby Gaspar. With over 25 years of experience as a physician and scientist, Bobby has played a pivotal role in redefining treatment options for severe genetic disorders. As the co-founder and current CEO of Orchard Therapeutics, recently acquired by Kyowa Kirin, Bobby has been at the forefront of advancing gene therapy, particularly in hematopoietic stem cell gene therapy. His groundbreaking work includes some of ...
All content for Between the Biotech Waves is the property of Nessan Bermingham PhD and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Today’s episode features a remarkable leader in the field of gene therapy, Dr. Bobby Gaspar. With over 25 years of experience as a physician and scientist, Bobby has played a pivotal role in redefining treatment options for severe genetic disorders. As the co-founder and current CEO of Orchard Therapeutics, recently acquired by Kyowa Kirin, Bobby has been at the forefront of advancing gene therapy, particularly in hematopoietic stem cell gene therapy. His groundbreaking work includes some of ...
Episode 24: A Between the Biotech Waves conversation with John Hoffman, managing director & head of healthcare equity capital markets at Credit Suisse
Between the Biotech Waves
51 minutes
2 years ago
Episode 24: A Between the Biotech Waves conversation with John Hoffman, managing director & head of healthcare equity capital markets at Credit Suisse
I am delighted to welcome back John Hoffman to Between the Biotech Waves. John is managing director & head of healthcare equity capital markets at Credit Suisse. In mid 2022 John joined the podcast to discuss the market outlook for ’22 and many of his predictions were spot on. It was also one of the most downloaded podcasts of the year. I am welcoming him back to review ’22, lessons learned and crystal ball gaze into ’23. What are we seeing overall in the capital markets, is M&A now o...
Between the Biotech Waves
Today’s episode features a remarkable leader in the field of gene therapy, Dr. Bobby Gaspar. With over 25 years of experience as a physician and scientist, Bobby has played a pivotal role in redefining treatment options for severe genetic disorders. As the co-founder and current CEO of Orchard Therapeutics, recently acquired by Kyowa Kirin, Bobby has been at the forefront of advancing gene therapy, particularly in hematopoietic stem cell gene therapy. His groundbreaking work includes some of ...
